Millennium Management’s Matinas BioPharma MTNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-356
Closed -$6.4K 6399
2023
Q2
$6.4K Sell
356
-3,883
-92% -$90.5K ﹤0.01% 5828
2023
Q1
$100K Sell
4,239
-549
-11% -$13.9K ﹤0.01% 5427
2022
Q4
$120K Buy
+4,788
New +$159K ﹤0.01% 5513
2021
Q2
Sell
-588
Closed -$31K 6883
2021
Q1
$31K Sell
588
-8,191
-93% -$549K ﹤0.01% 5802
2020
Q4
$597K Buy
8,779
+7,807
+803% +$362K ﹤0.01% 4068
2020
Q3
$37 Sell
972
-7,023
-88% -$279K ﹤0.01% 4318
2020
Q2
$309K Sell
7,995
-11,175
-58% -$429K ﹤0.01% 3646
2020
Q1
$575K Buy
19,170
+17,284
+916% +$1.04M ﹤0.01% 2799
2019
Q4
$214K Sell
1,886
-5,885
-76% -$341K ﹤0.01% 3843
2019
Q3
$244K Sell
7,771
-3,655
-32% -$132K ﹤0.01% 3679
2019
Q2
$489K Sell
11,426
-7,952
-41% -$382K ﹤0.01% 3251
2019
Q1
$1.06M Buy
+19,378
New +$1.04M ﹤0.01% 2831
2018
Q4
Sell
-1,496
Closed -$69K 4027
2018
Q3
$69K Sell
1,496
-2,970
-67% -$63.8K ﹤0.01% 3776
2018
Q2
$97K Buy
+4,466
New +$129K ﹤0.01% 3654
2017
Q3
Sell
-1,015
Closed -$86K 3734
2017
Q2
$86K Sell
1,015
-5,148
-84% -$691K ﹤0.01% 3316
2017
Q1
$854K Buy
+6,163
New +$1M ﹤0.01% 2494

Other funds holding MTNB

Millennium Management's MTNB Position: Q3 2023 in Review

Millennium Management sold out of Matinas BioPharma (MTNB) in Q3 2023, closing a stake of 356 shares — an estimated $6.4K sold.

Millennium Management first reported a position in MTNB in Q1 2017 and held it in 16 quarters. The position peaked at $1.06M in Q1 2019. 47 funds tracked by Wall St. Rank hold MTNB as of Q3 2023.

  • Millennium Management reported no remaining Matinas BioPharma position as of Q3 2023 after selling out during the quarter.
  • Millennium Management sold 356 Matinas BioPharma shares in Q3 2023, an estimated $6.4K.
  • Millennium Management first reported a position in Matinas BioPharma in Q1 2017 and held it in 16 quarters.
  • Millennium Management's Matinas BioPharma position peaked at $1.06M in Q1 2019.
  • 47 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2023.

Based on Millennium Management's 13F filing for Q3 2023, filed 14 Nov 2023.